Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Fulcrum Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 126
- +25 vs. Q4 2023
- Shares held
- 60.4M
- −705.2K (−1.2%) vs. Q4 2023
- Total value
- $569.7M
- +$157.4M (+38.2%) vs. Q4 2023
- New holders
- 36
- 33 more added
- Sold out
- 11
- 29 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FULC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 154 | $291.3M |
| Q1 2026 | 169 | $550.1M |
| Q4 2025 | 172 | $762.7M |
| Q3 2025 | 129 | $494.9M |
| Q2 2025 | 122 | $374.5M |
| Q1 2025 | 117 | $147.8M |
| Q4 2024 | 119 | $243.4M |
| Q3 2024 | 130 | $196.4M |
| Q2 2024 | 121 | $402.0M |
| Q1 2024 | 126 | $569.7M |
| Q4 2023 | 101 | $412.3M |
| Q3 2023 | 81 | $250.4M |
| Q2 2023 | 88 | $183.2M |
| Q1 2023 | 116 | $172.2M |
| Q4 2022 | 110 | $368.5M |
| Q3 2022 | 105 | $422.1M |
| Q2 2022 | 102 | $196.6M |
| Q1 2022 | 108 | $929.9M |
| Q4 2021 | 110 | $657.3M |
| Q3 2021 | 101 | $1.03B |
| Q2 2021 | 67 | $280.8M |
| Q1 2021 | 68 | $317.0M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Fulcrum Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC | 550,339 | $5.20M | 0.84% | +425,339+340.3% | Added |
| Susquehanna International Group, LLP | 560,992 | $5.30M | 0.01% | −105,601−15.8% | Reduced |
| Geode Capital Management, LLC | 563,458 | $5.32M | 0.00% | +10,228+1.8% | Added |
| D. E. Shaw & Co., Inc. | 625,176 | $5.90M | 0.01% | +127,497+25.6% | Added |
| Simplify Asset Management Inc. | 676,031 | $6.38M | 0.61% | +112,706+20.0% | Added |
| Vestal Point Capital, LP | 695,000 | $6.56M | 0.54% | −330,000−32.2% | Reduced |
| Qube Research & Technologies Ltd | 723,163 | $6.83M | 0.01% | +480,255+197.7% | Added |
| Rock Springs Capital Management LP | 727,673 | $6.87M | 0.17% | 00.0% | Unchanged |
| Propel Bio Management, LLC | 750,000 | $7.08M | 4.12% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 810,270 | $7.65M | 0.00% | −61,233−7.0% | Reduced |
| Deutsche Bank AG | 823,098 | $7.77M | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 897,461 | $8.47M | 0.01% | +459,958+105.1% | Added |
| Adage Capital Partners GP, L.L.C. | 1,106,422 | $10.4M | 0.02% | −400,000−26.6% | Reduced |
| MPM Oncology Impact Management LP | 1,137,108 | $10.7M | 1.73% | +1,137,108 | New |
| Jefferies Financial Group Inc. | 1,151,726 | $10.9M | 0.22% | −281,590−19.6% | Reduced |
| Morgan Stanley | 1,157,137 | $10.9M | 0.00% | −61,922−5.1% | Reduced |
| Dimensional Fund Advisors LP | 1,304,812 | $12.3M | 0.00% | +329,533+33.8% | Added |
| Citadel Advisors LLC | 1,325,379 | $12.5M | 0.01% | −78,494−5.6% | Reduced |
| BlackRock Inc. | 1,541,209 | $14.5M | 0.00% | −20,657−1.3% | Reduced |
| TRV GP IV, LLC | 2,343,154 | $22.1M | 10.72% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,538,665 | $24.0M | 0.00% | +18,681+0.7% | Added |
| Suvretta Capital Management, LLC | 2,848,486 | $26.9M | 1.13% | −2,670,395−48.4% | Reduced |
| Cowen and Company, LLC | 3,713,934 | $35.1M | 1.37% | +240,000+6.9% | Added |
| FMR LLC | 5,364,665 | $50.6M | 0.00% | −319,950−5.6% | Reduced |
| RTW Investments, LP | 5,845,956 | $55.2M | 0.81% | +376,000+6.9% | Added |
| Ra Capital Management, L.P. | 11,609,704 | $109.6M | 1.39% | 00.0% | Unchanged |
| Logos Global Management LP | 0 | $0 | 0.00% | −1,200,000−100.0% | Sold out |
| ClariVest Asset Management LLC | 0 | $0 | 0.00% | −106,977−100.0% | Sold out |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −46,778−100.0% | Sold out |
| MYDA Advisors LLC | 0 | $0 | 0.00% | −29,370−100.0% | Sold out |
| Sofinnova Investments, Inc. | 0 | $0 | 0.00% | −28,600−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −19,831−100.0% | Sold out |
| Mirabella Financial Services LLP | 0 | $0 | 0.00% | −16,914−100.0% | Sold out |
| LM Advisors LLC | 0 | $0 | 0.00% | −16,132−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −14,200−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −11,730−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −11,684−100.0% | Sold out |